You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,801,823


✉ Email this page to a colleague

« Back to Dashboard


Title:Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
Inventor(s): Krishnamurthy; Thinnayam N. (Scarborough, CA), Darke; Andrew (Newmarket, CA)
Assignee: RHODES PHARMACEUTICALS L.P. (Coventry, RI)
Filing Date:May 21, 2015
Application Number:14/718,814
Claims:1. A formulation comprising: a plurality of substrates comprising a portion of an effective dose of methylphenidate or a pharmaceutically acceptable salt coated with a hydrophobic material in an amount to obtain a weight gain from about 2% to about 25%, the hydrophobic material comprising a first acrylic polymer, an enteric coating applied over said hydrophobic material in an amount sufficient to delay the release of said portion until after said formulation passes through the stomach, wherein said enteric coating is derived from an aqueous dispersion comprising a second acrylic polymer, the formulation further comprising the remaining portion of said dose in an immediate release form, wherein the formulation provides a biphasic release profile, a mean maximum plasma concentration of said methylphenidate at about 2 hours and methylphenidate plasma concentrations below effective plasma concentration at about 8 hour to about 12 hours after an oral administration.

2. The formulation of claim 1, wherein the formulation provides an in-vitro dissolution as follows: TABLE-US-00034 Time % Methylphenidate (hours) Dissolved 0.25 0-45% 1 5-50% 4 40-90% 8 NLT 60% 12 NLT 80%.

3. The formulation of claim 1, wherein said remaining portion is included as an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, or an immediate release layer over said enteric coating.

4. The formulation of claim 1, which provides a peak plasma concentration of the methylphenidate which is from about 1.0 to about 2.0 times the plasma concentration of the methylphenidate provided by the formulation at about 9 hours after said administration.

5. The formulation of claim 1, wherein methylphenidate plasma concentration falls below effective plasma concentration at about 12 hours after said administration.

6. The formulation of claim 1 which is a capsule.

7. A formulation comprising: a plurality of substrates comprising a portion of an effective dose of methylphenidate or a pharmaceutically acceptable salt coated with a hydrophobic material in an amount to obtain a weight gain from about 2% to about 25%, the hydrophobic material comprising an alkylcellulose, a first acrylic polymer or mixtures thereof, an enteric coating applied over said hydrophobic material in an amount sufficient to delay the release of said portion until after said formulation passes through the stomach, wherein said enteric coating is derived from an aqueous dispersion comprising a second acrylic polymer, the formulation further comprising the remaining portion of said dose in an immediate release form, wherein the formulation provides a mean AUC.sub.0-t of 48493.80 pg.times.h/ml, a mean AUC.sub.0-inf of 51213.86 pg.times.h/ml, a mean C.sub.max of 4410.25 pg/ml, a mean T.sub.max of 3.27 hours, a mean K.sub.el of 0.1672 h.sup.-1, and a mean T.sub.1/2 el of 4.32 hours, based on a fasting administration of a formulation comprising 20 mg of said methylphenidate.

8. The formulation of claim 7, wherein the formulation provides an in-vitro dissolution as follows: TABLE-US-00035 Time % Methylphenidate (hours) Dissolved 0.25 0-45% 1 5-50% 4 40-90% 8 NLT 60% 12 NLT 80%.

9. The formulation of claim 7, wherein said remaining portion is included as an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, or an immediate release layer over said enteric coating.

10. The formulation of claim 7, which provides a peak plasma concentration of the methylphenidate which is from about 1.0 to about 2.0 times the plasma concentration of the methylphenidate provided by the formulation at about 9 hours after said administration.

11. The formulation of claim 7, wherein methylphenidate plasma concentration falls below effective plasma concentration at about 8 to about 12 hours after said administration.

12. The formulation of claim 7, which is a capsule.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.